FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011668093> ?p ?o ?g. }

• W3011668093 abstract "e18030 Background: Reversible tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) significantly increase survival for patients with previously treated advanced non-small cell lung cancer (NSCLC). Some studies have shown that most of responders to TKIs failed due to the appearance of new lesions without progression of the pre-existing target lesions. Methods: We retrospectively reviewed patients with advanced NSCLC diagnosed from 2005 to 2010 at two different hospitals in Catalonia (Spain) to identify those treated with TKIs. Patients with a clinical objective benefit as defined by Jackman were included. We analyzed both the clinical features of patients and their failure pattern. Results: There were 34 patients, 14 were women, with a median age of 64 years (range: 38 -81 years). Twenty-seven cases were adenocarcinoma while only 3 were squamous cell carcinoma. Eleven patients had never smoked. Previously to TKI, all patients received at least one line of chemotherapy except nine patients who received TKI as first-line treatment. Median time to progression after initiation of TKI was 8.7 months (1.9 - 38.9 months). Radiological TKI response was CR/PR/SD: 1/15/17 (1 not available). Rash and diarrhea were the most common toxic effects. No grade 3 or 4 toxicities were observed. TKI was discontinued in all patients after disease progression; 12 patients were unable to receive further therapy due to symptomatic deterioration. In 19 patients, PD was due to the appearance of new lesions and not to progression of the pre-existing lesions. Results of mutations of EGFR were available in 7 patients (ratio of mutant/wild status was 5/2). In all patients with known EGFR mutation, only new lesions leaded to progression. Conclusions: In spite of our series’ heterogeneity, results are consistent with previous data and suggest that a wide range of patients can benefit from TKIs. Furthermore, more than half of progressions were due to new lesions. Patients with known EGFR mutation strictly followed this failure pattern, though larger studies in EGFR mutated patients are needed to assess both failure patterns and benefits of continuing TKIs after progression when pre-existing lesions are stable." @default.
• W3011668093 created "2020-03-23" @default.
• W3011668093 creator A5004298052 @default.
• W3011668093 creator A5009145670 @default.
• W3011668093 creator A5016460887 @default.
• W3011668093 creator A5041843240 @default.
• W3011668093 creator A5045627245 @default.
• W3011668093 creator A5060532164 @default.
• W3011668093 creator A5065362834 @default.
• W3011668093 creator A5079585672 @default.
• W3011668093 date "2012-05-20" @default.
• W3011668093 modified "2023-09-26" @default.
• W3011668093 title "Failure pattern after response to reversible tyrosine kinase inhibitors in advanced non-small cell lung cancer." @default.
• W3011668093 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e18030" @default.
• W3011668093 hasPublicationYear "2012" @default.
• W3011668093 type Work @default.
• W3011668093 sameAs 3011668093 @default.
• W3011668093 citedByCount "0" @default.
• W3011668093 crossrefType "journal-article" @default.
• W3011668093 hasAuthorship W3011668093A5004298052 @default.
• W3011668093 hasAuthorship W3011668093A5009145670 @default.
• W3011668093 hasAuthorship W3011668093A5016460887 @default.
• W3011668093 hasAuthorship W3011668093A5041843240 @default.
• W3011668093 hasAuthorship W3011668093A5045627245 @default.
• W3011668093 hasAuthorship W3011668093A5060532164 @default.
• W3011668093 hasAuthorship W3011668093A5065362834 @default.
• W3011668093 hasAuthorship W3011668093A5079585672 @default.
• W3011668093 hasConcept C126322002 @default.
• W3011668093 hasConcept C170493617 @default.
• W3011668093 hasConcept C184235292 @default.
• W3011668093 hasConcept C2776256026 @default.
• W3011668093 hasConcept C42362537 @default.
• W3011668093 hasConcept C502942594 @default.
• W3011668093 hasConcept C71924100 @default.
• W3011668093 hasConcept C86803240 @default.
• W3011668093 hasConcept C95444343 @default.
• W3011668093 hasConceptScore W3011668093C126322002 @default.
• W3011668093 hasConceptScore W3011668093C170493617 @default.
• W3011668093 hasConceptScore W3011668093C184235292 @default.
• W3011668093 hasConceptScore W3011668093C2776256026 @default.
• W3011668093 hasConceptScore W3011668093C42362537 @default.
• W3011668093 hasConceptScore W3011668093C502942594 @default.
• W3011668093 hasConceptScore W3011668093C71924100 @default.
• W3011668093 hasConceptScore W3011668093C86803240 @default.
• W3011668093 hasConceptScore W3011668093C95444343 @default.
• W3011668093 hasLocation W30116680931 @default.
• W3011668093 hasOpenAccess W3011668093 @default.
• W3011668093 hasPrimaryLocation W30116680931 @default.
• W3011668093 hasRelatedWork W1989206024 @default.
• W3011668093 hasRelatedWork W2015831475 @default.
• W3011668093 hasRelatedWork W2030164113 @default.
• W3011668093 hasRelatedWork W2145580674 @default.
• W3011668093 hasRelatedWork W2164207083 @default.
• W3011668093 hasRelatedWork W2273208817 @default.
• W3011668093 hasRelatedWork W2331218542 @default.
• W3011668093 hasRelatedWork W2411963933 @default.
• W3011668093 hasRelatedWork W2437093013 @default.
• W3011668093 hasRelatedWork W2465263782 @default.
• W3011668093 hasRelatedWork W2589039067 @default.
• W3011668093 hasRelatedWork W2698318545 @default.
• W3011668093 hasRelatedWork W2717400244 @default.
• W3011668093 hasRelatedWork W2756128561 @default.
• W3011668093 hasRelatedWork W2797901267 @default.
• W3011668093 hasRelatedWork W2892018778 @default.
• W3011668093 hasRelatedWork W2966216520 @default.
• W3011668093 hasRelatedWork W2981497803 @default.
• W3011668093 hasRelatedWork W3024485728 @default.
• W3011668093 hasRelatedWork W3032800087 @default.
• W3011668093 isParatext "false" @default.
• W3011668093 isRetracted "false" @default.
• W3011668093 magId "3011668093" @default.
• W3011668093 workType "article" @default.